Drug details

Refacto (antihemophilic factor)

type of

ReFacto (antihemophilic factor, recombinant) is a protein used to treat or prevent bleeding episodes in adults and children with hemophilia A. ReFacto is also used to control bleeding related to surgery or dentistry in a person with hemophilia, and to prevent joint damage in people age 16 or older with severe hemophilia A and no prior joint damage. ReFacto is not for use in people with von Willebrand disease. ReFacto is available in generic form.

This drug may have the following side effects:
  • sore throat
  • redness
  • itching
  • cough
  • stinging
  • runny nose; fever or chills; mild nausea
  • vomiting; unusual or unpleasant taste in your mouth; skin itching or rash; warmth
  • pain,or
  • irritation where the injection was given
The following drugs are related to Refacto, either as a replacement or used together:
  • Advate ([antihemophilic factor (recombinant), plasma/albumin-free method] for intravenous injection)
  • Kogenate FS (antihemophilic factor (recombinant))
  • Kovaltry (antihemophilic factor (recombinant) for intravenous administration)
  • Novoeight (antihemophilic factor (recombinant) lyophilized powder for intravenous injection)
  • Eloctate (antihemophilic factor (recombinant), fc fusion protein for intravenous infusion)
  • Rixubis (coagulation factor ix (recombinant) for intramuscular injection)
  • Esperoct ([antihemophilic factor (recombinant), glycopegylated-exei] injection)